{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?identifier=63867", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=63867", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?identifier=63867&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?identifier=63867&_page=0", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?identifier=63867", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?identifier=63867", "items" : [{"_about" : "http://data.parliament.uk/resources/1363463", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1363463/answer", "answerText" : {"_value" : "

The Government\u2019s approach to seeking a vaccine for COVID-19 has, from the outset, been to take a portfolio approach to vaccine procurement. This has allowed the Government to secure access to six different vaccine candidates across three vaccine types and from a range of developers. The aim is to ensure that the UK has access to the most promising vaccines currently in development, should any of these prove safe and effective.<\/p>

<\/p>

While there are currently no approved nasal vaccines for COVID-19, the Government continues to engage with the market as new vaccines and vaccine technologies gain approval.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2021-11-01", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-11-01T17:21:55.15Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2021-10-26", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment his Department has made of the feasibility of introducing nasal vaccines as part of the Government's covid-19 vaccination programme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4667", "label" : {"_value" : "Biography information for Mike Amesbury"} } , "tablingMemberConstituency" : {"_value" : "Weaver Vale"} , "tablingMemberPrinted" : [{"_value" : "Mike Amesbury"} ], "uin" : "63867"} , {"_about" : "http://data.parliament.uk/resources/687934", "AnsweringBody" : [{"_value" : "Church Commissioners"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/687934/answer", "answerText" : {"_value" : "

The number of non-staff security passes issued by the National Church Institutions, of which the Church Commissioners are a member, fall into the following categories:<\/p>

1. Senior members and staff of the General Synod (Church of England\u2019s Governing Parliament) in the following categories:<\/p>